摘要
本研究应用抗小鼠宫颈癌单克隆抗体ＡＵ_１４－１所建立的夹心ＥＬＩＳＡ法，测定了人血清宫颈癌抗原．以４０例正常妇女血清的Ａ４９０均值加３个标准差之和（０．２０Ａ４９０Ｕ）作为阳性阈值，对２５例宫颈癌、５２例宫颈炎和１２例其他妇科疾患病人血清进行检测，结果宫颈癌为２５／２５阳性，宫颈炎２／５２阳性（其中１例阳性者为重度宫颈糜烂），其他妇科疾患均为阴性．此外，１例卵巢癌腹水亦为阴性．经统计学分析，ＡＵ１４－１确定的宫颈癌抗原存在于宫颈鳞癌和腺癌病人血清中，其阳性率均为１００％，敏感性１００％，特异性９６．２％．与目前研究的宫颈癌血清标志物ＳＣＣ和ＣＡ—１２５比较，ＡＵ１４－１—ＥＬＩＳＡ对人血清官颈癌抗原的检测，具有较高的敏感性和特异性以及较好的临床应用前景，并进一步证明了肿瘤“进化抗原”的理论．
The monoclonal antibody against mouse cervical cancer,designated AU14-1,was conjugatedto horseradish Peroxidase(HRP)and a sandwich ELISA with AU14-1 and HRP-AUI14-1 conjugatewas established. By this immunoassay, positive resultS were found in the 25 PatientS with cervical cancer including 19 cases with squamous cell carcinoma,4 adenocarcinoma,I clear cell carcionma and 1malignant mixed mesomerdal), in none of the 40 normal females, 2 of the 52 PatientS with cervicitis andnone of the 12 cases of other gynecological diseases.In addition,one of bloody ascites from a Patientwith ovarian cancer was also negative.It showed that the sandwich ELISA With McAb AU14--lwe usedhad better sensitivity and speCificity than those of assays for other serum markers(SCC and CA--125)of cervical carcionma and it appeared promising for clinical application.It also further verified the theory of 'evoluhon antigen'in tumor.
